STOCK TITAN

Pacira Biosciences Inc - PCRX STOCK NEWS

Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.

Overview

Pacira BioSciences Inc (NASDAQ: PCRX) is a specialty pharmaceutical company committed to revolutionizing pain management by offering innovative non-opioid therapies and regenerative health solutions. With a core focus on providing safe and effective alternatives for pain control, the company leverages its proprietary drug delivery platforms to address acute pain in surgical and chronic conditions. Its approach combines advanced pharmaceutical formulations with novel medical devices, ensuring that clinicians have access to effective treatment options that reduce reliance on opioids.

Core Technologies and Products

At the heart of Pacira's innovation is its unique product delivery technology, which encapsulates active compounds without altering their molecular structures. This platform enables controlled, extended release of medications, ensuring long-lasting efficacy. The company has successfully commercialized several non-opioid treatments:

  • EXPAREL: A long-acting local anesthetic designed to provide postsurgical pain control through sustained drug release, thereby reducing the need for opioids.
  • ZILRETTA: An extended-release intra-articular injection indicated for the management of osteoarthritis knee pain, offering patients prolonged relief.
  • iovera®: A handheld, drug-free device that applies controlled doses of cold therapy to targeted nerves, providing immediate and lasting pain relief.

In addition to these commercial products, Pacira is advancing its pipeline with a novel gene therapy candidate, PCRX-201. This locally administered therapy aims to treat osteoarthritis by regulating inflammatory pathways, thus addressing the root causes of pain and disability.

Market Position and Business Model

Pacira BioSciences operates at the intersection of innovative drug delivery and non-opioid pain management solutions. Its business model emphasizes:

  • Commercialization of Proven Therapies: The company has established a presence in markets requiring effective postsurgical and chronic pain management solutions, evidenced by the wide adoption of its therapies in diverse clinical settings.
  • Advanced R&D and Pipeline Development: By investing in robust research and development programs, along with strategic partnerships, Pacira continues to expand its portfolio and maintain competitive differentiation in the specialty pharmaceutical sector.
  • Regulatory and Reimbursement Strategies: With products that have secured critical reimbursement designations, Pacira enhances market access for its non-opioid therapies across different healthcare settings. This strategic emphasis supports clinician adoption and broader patient access.

Clinical and Commercial Significance

The company's focus on non-opioid pain management comes at a time when reducing opioid dependency is an urgent priority in healthcare. By developing treatments that not only manage pain effectively but also minimize opioid consumption, Pacira is addressing a key public health challenge. Its clinically validated products have been incorporated into pain management protocols in hospitals and outpatient settings alike, offering enduring benefits for patients and healthcare providers.

Innovative Edge and Future Pipeline

Pacira’s utilization of advanced drug delivery systems, such as multivesicular liposomes and precise cryoneurolysis, underscores its commitment to innovation. These technologies not only improve therapeutic outcomes but also facilitate streamlined billing and regulatory approval processes through established coding systems. With an evolving pipeline that includes gene therapy approaches, the company is poised to expand its reach into additional therapeutic areas, addressing unmet needs in the treatment of chronic and musculoskeletal pain.

Competitive Landscape and Differentiators

In a competitive market, Pacira differentiates itself through its deep expertise in non-opioid pain management and its commitment to technological advancements. The integration of robust clinical data, strategic reimbursement initiatives, and a focus on delivering sustained therapeutic benefits positions the company as a trusted innovator among healthcare practitioners. Unlike traditional pain management solutions that rely heavily on opioids, Pacira’s products are designed to provide effective relief with reduced risk of dependency, offering a clinically superior alternative in the evolving landscape of pain management.

Conclusion

With a comprehensive portfolio that spans commercial-stage products and a promising pipeline, Pacira BioSciences Inc stands as a key player in the specialty pharmaceutical industry. Its ongoing commitment to developing non-opioid pain therapies, underpinned by advanced drug delivery technologies and rigorous clinical validation, ensures that it remains an authoritative source of innovation and expertise in pain management and regenerative health.

Rhea-AI Summary
Pacira BioSciences, Inc. receives RMAT designation from FDA for PCRX-201 gene therapy product candidate for osteoarthritis. Positive Phase 1 study results show efficacy for at least 52 weeks. Additional data to be presented at OARSI 2024. RMAT designation expedites development process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
-
Rhea-AI Summary
Pacira BioSciences, Inc. (PCRX) will participate in an analyst-led fireside chat at the Barclays 26th Annual Global Healthcare Conference. The event will take place on March 13, 2024, in Miami, at 1:35 PM ET. Live audio can be accessed on the company's website. A replay will be available for two weeks post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
conferences
-
Rhea-AI Summary
Pacira BioSciences, Inc. (PCRX) reported record revenues of $675 million in 2023, with full-year GAAP net income of $42 million and adjusted EBITDA of $214 million. EXPAREL surpassed the 14 million patient mark, and the FDA approved new manufacturing suite and label expansions. The company appointed Frank D. Lee as CEO, aiming for long-term growth and operational excellence in pain management solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
Rhea-AI Summary
Pacira BioSciences, Inc. (PCRX) will release its Q4 and full-year 2023 financial results on February 29, 2024. A live conference call and webcast will follow, allowing participants to engage in a Q&A session. The event will be accessible via webcast and replay options for those unable to join live.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences earnings
-
Rhea-AI Summary
Pacira BioSciences, Inc. announced positive results from a Phase 3 study on EXPAREL for sciatic nerve block in bunionectomy patients. The study showed significant pain reduction and opioid consumption over 96 hours compared to bupivacaine HCl, with EXPAREL leading to 61% fewer opioids used and 24.4% of patients not needing rescue opioids. The safety profiles of EXPAREL and bupivacaine HCl were similar, with mild to moderate adverse events. EXPAREL offers a non-opioid pain management solution for foot and ankle procedures, enhancing outpatient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
none
-
Rhea-AI Summary
Pacira BioSciences, Inc. (PCRX) has secured a national group purchasing agreement for Brand Pharmaceuticals with Premier, Inc., effective January 1, 2024. This agreement allows Premier members to access special pricing for EXPAREL® (bupivacaine liposome injectable suspension), a single-dose local and regional analgesic, aimed at improving patient care and reducing reliance on opioids. The collaboration is expected to expand Pacira's reach and provide non-opioid pain management options to more patients. Premier, with its extensive network of U.S. hospitals and health systems, aims to transform healthcare by enabling better care and outcomes at a lower cost.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.44%
Tags
none
Rhea-AI Summary
Paradise PB Events and G.O.A.T. Paddle announced the expansion of G.O.A.T. Bowl I tournament play in Las Vegas to 24 teams and the signing of new sponsors. The tournament is set for Feb. 9 and will feature a full day of pickleball festivities, including amateur competition, food truck line-up, tailgate party, skills challenge, and festival atmosphere. The expansion is due to high demand for participation from the pickleball community. The tournament is produced by Paradise PB Events and presented by Pacira BioSciences' ZILRETTA®. Oso Pickleball has been named the official ball sponsor, and Dunkin' has been added to the line-up of event supporters.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
none
-
Rhea-AI Summary
Pacira BioSciences, Inc. (Nasdaq: PCRX) reported preliminary unaudited total revenue of $675.0 million for the year ended December 31, 2023, compared with $666.8 million for the year ended December 31, 2022. The company's fourth quarter EXPAREL net product sales were $143.9 million in 2023, with a 4% average daily volume growth. Full-year EXPAREL net product sales were $538.1 million in 2023, with a 5% average daily volume growth. The company also announced plans for long-term growth initiatives and the upcoming launch of EXPAREL in two key lower extremity nerve blocks in 2024, as well as the expansion of patient access with the rollout of the NOPAIN Act in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
none
-
Rhea-AI Summary
Pacira BioSciences, Inc. (PCRX) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
conferences
Rhea-AI Summary
Pacira BioSciences, Inc. (Nasdaq: PCRX) appoints Frank D. Lee as CEO and member of the Board, effective January 2, 2024. Paul J. Hastings named Chair of the Board. David Stack to remain in advisory role through August 2025. Lee brings more than three decades of global experience in pharmaceutical and biotechnology product development and commercialization. He has a strong track record of leadership success and has held executive positions at Forma Therapeutics, Genentech, Novartis, Janssen, and Eli Lilly. Lee's appointment comes with inducement awards, including a non-qualified stock option and a restricted stock unit award.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
management

FAQ

What is the current stock price of Pacira Biosciences (PCRX)?

The current stock price of Pacira Biosciences (PCRX) is $24.89 as of April 2, 2025.

What is the market cap of Pacira Biosciences (PCRX)?

The market cap of Pacira Biosciences (PCRX) is approximately 1.1B.

What is the core focus of Pacira BioSciences Inc?

Pacira BioSciences Inc specializes in developing and commercializing innovative non-opioid pain management therapies and regenerative health solutions for both acute and chronic conditions.

How does Pacira differentiate its products in the market?

The company leverages proprietary drug delivery platforms and advanced technologies, such as multivesicular liposomes and cryoneurolysis, to deliver sustained pain relief with reduced opioid reliance.

What are the key commercial-stage products offered by Pacira?

Pacira’s main products include EXPAREL, a long-acting local anesthetic; ZILRETTA, an extended-release intra-articular injection for osteoarthritis knee pain; and iovera®, a handheld device that uses controlled cold therapy for drug-free pain control.

What technology underpins Pacira's drug delivery system?

The company utilizes a proprietary platform that encapsulates drugs in multivesicular liposomes, allowing for controlled, extended release of the active ingredient without altering its molecular structure.

How does Pacira address the issue of opioid dependency?

By developing effective non-opioid pain management options, Pacira reduces the reliance on opioids by offering alternatives that provide long-lasting pain relief, thereby addressing a significant public health concern.

What is PCRX-201 and what potential does it hold?

PCRX-201 is an emerging gene therapy candidate designed to treat osteoarthritis by reducing inflammation at the source. Its localized administration and innovative design offer a potential breakthrough in long-term pain management.

Which healthcare settings benefit from Pacira's therapies?

Pacira's products are used across a variety of settings, including hospital surgical departments, outpatient centers, and clinics, where effective pain management is critical for post-surgical recovery and chronic condition management.

What role do reimbursement strategies play in Pacira's business model?

Strategic reimbursement initiatives, such as securing unique coding for its products, streamline the billing process and enhance market access, ensuring that healthcare providers can readily adopt Pacira’s non-opioid solutions.

How does Pacira support clinical decision-making and patient care?

Through rigorous clinical validation, advanced drug delivery technologies, and continuous innovation, Pacira provides healthcare practitioners with reliable, evidence-based alternatives for effective pain management.
Pacira Biosciences Inc

Nasdaq:PCRX

PCRX Rankings

PCRX Stock Data

1.11B
44.62M
3.18%
111.99%
12.66%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
TAMPA